IMVT Immunovant Inc

Price (delayed)

$16.57

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

$1.2B

Sector: Healthcare
Industry: Biotechnology

Highlights

Immunovant's debt has decreased by 8% QoQ
IMVT's net income has plunged by 82% YoY and by 26% from the previous quarter
IMVT's quick ratio is down by 26% since the previous quarter

Key stats

What are the main financial stats of IMVT
Market
Shares outstanding
97.97M
Market cap
$1.62B
Enterprise value
$1.2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$100.16M
EBITDA
-$99.4M
Free cash flow
-$84.01M
Per share
EPS
-$1.33
Free cash flow per share
-$0.86
Book value per share
$4.23
Revenue per share
$0
TBVPS
$4.42
Balance sheet
Total assets
$433.03M
Total liabilities
$18.88M
Debt
$3.5M
Equity
$414.15M
Working capital
$412.94M
Liquidity
Debt to equity
0.01
Current ratio
26.05
Quick ratio
25.6
Net debt/EBITDA
4.21
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-31%
Return on equity
-32.9%
Return on invested capital
N/A
Return on capital employed
-24%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
-0.96%
1 week
-13.61%
1 month
-60.73%
1 year
11.73%
YTD
-64.13%
QTD
-64.13%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$99.68M
Net income
-$99.82M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 83% year-on-year and by 26% since the previous quarter
IMVT's net income has plunged by 82% YoY and by 26% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
3.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 3.1% QoQ
The stock's price to book (P/B) is 54% less than its last 4 quarters average of 8.6
The equity has contracted by 6% from the previous quarter

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity has surged by 81% year-on-year and by 5% since the previous quarter
IMVT's return on assets is up by 47% year-on-year and by 4.3% since the previous quarter

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total liabilities is up by 28% year-on-year and by 22% since the previous quarter
Immunovant's debt is 99% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.